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OBJECTIVES: To compare the efﬁ cacy and safety of a nifedipine sustained release 
(nifedipine SR), with ginkgo biloba extract as treatment for primary Raynaud’s phe-
nomenon in Korean. METHODS: ; Multi-centred, randomised, ﬂ exible dose and open 
study. A total of 134 patients with primary Raynaud’s phenomenon were selected from 
3 centers and randomly assigned to either the Nifedipine SR group (Group N) or the 
Ginkgo biloba extract group (Group G) in the ratio of 2:1. After a run-in period of 
two weeks, participants received treatment for eight weeks. Primary efﬁ cacy evaluation 
was any percent change of the Raynaud attack rate between the reference value before
treatment and after the 8-week treatment. A safety was also evaluated. RESULTS: ; 
Out of 134 patients with primary Raynaud’s phenomenon, 39 subjects dropped out
of the program during the selection period. Ninety-three subjects (70.5% of the origi-
nal pool) were randomly assigned, and 64 subjects (Group N: 42, Group G: 22) among 
the 93 completed this clinical trial. There were 24 male subjects (25.81%) and 69
female subjects(74.19%), and the average age of the subjects was 39.20 (Group N: 
37.67, Group G: 42.13). The percent change of the attack rate in Intention To Treat 
(ITT) group was 50.05% at 7 and 8 weeks after treatment in Group N, while it was 
just 31.02% in Group G (p-value  0.03). The improvement was shown to be much 
higher in Group N than in Group G. No difference in QOL items was found between
the two groups in this clinical trial. No signiﬁ cant adverse events occurred; severity 
of the adverse events incurred was mostly mild, and those adverse events were
improved without speciﬁ c treatment. CONCLUSIONS: Nifedipine SR was more effec-
tive pharmacotherapy than Ginkgo biloba for primary Raynaud’s phenomenon 
(Percent change of R : 50.1% vs. 31%). Both Nifedipine SR and Ginkgo biloba
showed tolerability without serious adverse events.
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OBJECTIVES: Aspirin may interact with ACE inhibitors to reduce their beneﬁ cial
effects in patients with heart failure. The objective of this retrospective cohort study
was to assess the risk of congestive heart failure (CHF) hospitalization in patients with
heart failure (HF) taking ACE inhibitors in a large national cohort of veterans.
METHODS: Exposure to aspirin was assessed between October 1, 2000 and Septem-
ber 30, 2001. Patients were characterized as prescribed: no aspirin, low-dose (a 81 mg)
aspirin, high-dose (81 mg) aspirin. Time to HF hospitalization in these selected 
patients was assessed between October 1, 2001 and September 30, 2002. Chi-square
tests, Kaplan-Meier plots and log-rank tests were employed for testing bivariate asso-
ciations. A multivariable Cox regression model was used to estimate the adjusted
hazard ratio for the risk of CHF hospitalization due to aspirin exposure after control-
ling for sociodemographic factors, comorbidities, comedications, and years with HF. 
RESULTS: The ﬁ nal study cohort consisted of 157,088 HF patients with a mean age
of 69.75 ( o 10.19) years. The crude HF hospitalization rates differed signiﬁ cantly
between the treatment groups (log-rank statistic for KM plot: p-value 0.001). In 
multivariate analysis of the association of aspirin use and hospitalization for CHF the 
use of both high-dose aspirin (HR 1.26, 95% CI 1.19–1.34) and low-dose aspirin (HR 
1.18, 95% CI 1.09–1.27) was associated with increased risk of CHF hospitalization
with no aspirin use as the reference group. The results remained the same for high-dose 
aspirin in case of patients: with both CHF and IHD, without IHD, age  65 years, 
age q 65 years and patients with Medication Possession Ratio (MPR) q 0.8. CONCLU-
SIONS: The theory of negative interaction between ACE inhibitors and aspirin may 
be true, but results must be interpreted with caution. Prospective studies would be
needed to investigate this interaction further.
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OBJECTIVES: Cardiovascular disease (CVD) is a leading cause of death in the US, 
but regular use of preventive low-dose aspirin has proven to be an effective way to
prevent CV events. The purpose of this study was to explore the potential economic
impact in the US if aspirin usage were to be increased in line with current clinical 
guidelines for primary and secondary prevention of CV events. METHODS: The 
risk proﬁ le of the US population was modeled using NHANES data and the Framing-
ham cardiovascular risk equations were applied to calculate risk for myocardial 
infarction, angina and stroke according to age and gender. Primary and secondary
prevention patient populations were considered separately. Using publicly available 
unit costs, a budget impact model calculated the annual impact of increased preventive 
aspirin usage considering adverse events and diminishing aspirin adherence over a 
ten-year time horizon. RESULTS: In a base population of 1,000,000 patients, imple-
mentation of current clinical guidelines would prevent an additional 1273 myocardial
infarctions, 2184 angina episodes and 565 strokes in primary prevention patients
and an additional 578 myocardial infarctions, and 607 strokes in secondary preven-
tion patients. Angina reduction was not assessed in secondary prevention patients.
This represents a total savings to the Managed Care Organization (MCO) of $84.9
million for primary prevention and $32.7 million for secondary prevention and addi-
tional out of pocket expense to patients of $32.1 million for primary prevention and 
$2.9 million for secondary prevention for the cost of aspirin. CONCLUSIONS: This 
model suggests that there is a strong economic case, both for payers as well as for 
society, to encourage aspirin use for patients at appropriate risk and per clinical
guidelines. It also provides an example of how minimizing costs does not necessarily 
have to imply rationing of care.
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OBJECTIVES: In China, increasing CHD patients accept PCI treatment, with about
40% GR annually from 1984 to 2005; however, some have alleged that it was 
abused. Further, the China Basic Medical Insurance (BMI) Authority also felt ﬁ nancial 
pressure due to the escalating use. Therefore, the China Health Insurance Research 
Association (CHIRA) decided to evaluate the value of coronary stenting as the evi-
dence for appropriate regulation. METHODS: This observational, prospective study 
involved 20 sites (13 cities). A total of 630 of 720 planned cases were recruited from
July 2005 to July 2006 with one year follow up. The study evaluated clinical and
economic value of stenting by collecting clinical, cost, and QoL data. Retrospective
data collected included reimbursement policy and actual claim data in 2005 and ﬁ rst 
half of 2006, to estimate the economic burden and budget impact and to analyze 
the cost-inﬂ uence factors. RESULTS: 1) There was generally not evident abuse in
PCI/stenting in the available data; 2) The effectiveness of PCI/stenting is favorable, 
with 1.43% complication, 0.98% death, 0.82% incidence of MI, and 1.79% of 
revascularization. All SEs are signiﬁ cantly lower than those seen published rates. The
QoL scores improved signiﬁ cantly (20, SF-36); 3) Stenting can gain $7100 per 
incremental QALY; 4) PCI fees are inﬂ uenced considerably by the number of diseased
vessels, co-morbidity, and reimbursement policy; 7) The price of PCI is lower than its 
cost, and thus it’s mainly reimbursed by pharmaceutical and device use; and 8) the 
economic burden of PCI was heavy in 2006. The out-of-pocket part of PCI was equal
to an employee’s average annual salary or twice that of a retiree’s pension. CONCLU-
SIONS: Stenting is cost effective with favorable QoL improvement. Therefore, it’s
worthwhile to further improve reimbursement regulations to release a patients’ eco-
nomic burden.
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OBJECTIVES: To construct a ﬂ exible Markov model allowing cost-effectiveness
analysis of different statin therapies over different time horizons in ACS patients in 
Germany. METHODS: A Markov model was designed to compare outcomes of 
intensive atorvastatin 80 mg versus standard simvastatin 20–40 mg treatment. Event 
rates for the ﬁ rst 5 years for MI, stroke, unstable angina, heart failure, revasculariza-
tion and cardiovascular death were derived from a post-hoc analysis of a subset of 
patients with recent ACS in the IDEAL study; extrapolation of event rates beyond the 
trial was based on risk-prediction equations from the Framingham study. Event and 
all-cause mortality were based on sources in literature. To estimate QALYs, utilities
were derived from the literature. Cost inputs were based on the German statutory 
health insurance perspective; patients’ co-payments were deducted. Costs of care for 
cardiovascular events were based on DRG costs for acute treatment, and on literature 
and expert panel results for subsequent costs. Univariate and probabilistic sensitivity
analyses were performed. All costs and beneﬁ ts were discounted by 5% annually, and
costs were reported in 2008 Euros. RESULTS: The base case used a one-year cycle
length, a lifetime time horizon, and a ﬁ ve-year treatment duration with high-dose
atorvastatin, after which all patients received simvastatin for life. For the base case, 
the incremental cost per life-year gained is €13,993, and the incremental cost per 
QALY gained is €14,168. At a threshold of €30,000 per QALY gained, sensitivity 
analysis predicted an 85% probability that atorvastatin 80 mg would be considered 
cost-effective compared with simvastatin 20–40 mg. CONCLUSIONS: The results can 
